Neogen(US:NEOG) ZACKSยท2025-04-09 23:00Core Insights - Neogen (NEOG) reported a revenue of $220.98 million for the quarter ended February 2025, reflecting a year-over-year decline of 3.4% and an EPS of $0.10, down from $0.12 in the same quarter last year [1] - The revenue fell short of the Zacks Consensus Estimate of $223.03 million by 0.92%, and the EPS was 23.08% below the consensus estimate of $0.13 [1] Revenue Breakdown - Animal Safety revenues totaled $68.25 million, slightly below the average estimate of $68.77 million, marking a 4% decline year-over-year [4] - Food Safety revenues were reported at $152.73 million, also below the average estimate of $154.26 million, representing a 3.2% decrease year-over-year [4] - Specific segments within Animal Safety showed varied performance, with Life Sciences revenues increasing by 9.6% to $1.50 million, while Veterinary Instruments & Disposables fell by 14.3% to $15.41 million [4] - In Food Safety, revenues from Natural Toxins & Allergens decreased by 10.9% to $17.60 million, while Rodent Control, Insect Control & Disinfectants increased by 16.6% to $11.82 million [4] - Genomics Services in Animal Safety significantly outperformed estimates, reporting $17.01 million against an average estimate of $6.43 million [4] - Conversely, Food Safety Genomics Services reported $5.70 million, falling short of the average estimate of $18.46 million [4] Stock Performance - Neogen's shares have declined by 28.8% over the past month, compared to a 13.5% decline in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]